NRX Pharmaceuticals, Inc.
NRXP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001719406
No open-market purchases or sales by NRX Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $47.6M in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in NRX Pharmaceuticals, Inc. as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −3 vs. Q4 2024
- Shares held
- 2.26M
- +1.21M (+115.6%) vs. Q4 2024
- Total value
- $4.60M
- +$2.30M (+99.5%) vs. Q4 2024
- New holders
- 4
- 6 more added
- Sold out
- 7
- 5 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRXP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 47 | $47.6M |
| Q1 2026 | 33 | $13.2M |
| Q4 2025 | 28 | $14.2M |
| Q3 2025 | 24 | $13.0M |
| Q2 2025 | 25 | $9.76M |
| Q1 2025 | 22 | $4.60M |
| Q4 2024 | 25 | $2.31M |
| Q3 2024 | 18 | $1.21M |
| Q2 2024 | 19 | $1.29M |
| Q1 2024 | 31 | $1.76M |
| Q4 2023 | 30 | $1.84M |
| Q3 2023 | 34 | $964.7K |
| Q2 2023 | 32 | $4.78M |
| Q1 2023 | 30 | $2.07M |
| Q4 2022 | 33 | $3.44M |
| Q3 2022 | 30 | $3.04M |
| Q2 2022 | 37 | $2.18M |
| Q1 2022 | 34 | $25.1M |
| Q4 2021 | 38 | $12.4M |
| Q3 2021 | 23 | $16.2M |
| Q2 2021 | 18 | $18.9M |
| Q1 2021 | 1 | $4.00K |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding NRX Pharmaceuticals, Inc.; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Anson Funds Management LP | 1,179,061 | $2.42M | 0.58% | +993,401+535.1% | Added |
| Vanguard Group Inc | 388,925 | $797.3K | 0.00% | +148,609+61.8% | Added |
| AdvisorShares Investments LLC | 286,797 | $556.4K | 0.11% | −23,517−7.6% | Reduced |
| Geode Capital Management, LLC | 134,657 | $276.1K | 0.00% | +60,406+81.4% | Added |
| Marshall Wace, LLP | 89,086 | $182.6K | 0.00% | +89,086 | New |
| State Street Corp | 43,724 | $89.6K | 0.00% | +27,000+161.4% | Added |
| Two Sigma Investments, LP | 30,146 | $61.8K | 0.00% | +30,146 | New |
| BlackRock, Inc. | 29,075 | $59.6K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 28,601 | $58.6K | 0.00% | +28,601 | New |
| TownSquare Capital, LLC | 15,041 | $30.8K | 0.00% | 00.0% | Unchanged |
| One Wealth Management Investment & Advisory Services, LLC | 15,041 | $30.8K | 0.05% | 00.0% | Unchanged |
| Morgan Stanley | 11,896 | $24.4K | 0.00% | +7,500+170.6% | Added |
| Bank of America Corp | 3,343 | $6.85K | 0.00% | +45+1.4% | Added |
| Wells Fargo & Company | 2,160 | $4.43K | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 2,000 | $4.10K | 0.00% | +2,000 | New |
| Simplex Trading, LLC | 633 | $1.00K | 0.00% | −368−36.8% | Reduced |
| UBS Group AG | 105 | $215 | 0.00% | −45−30.0% | Reduced |
| Advisor Group Holdings, Inc. | 90 | $184 | 0.00% | 00.0% | Unchanged |
| Carolina Wealth Advisors, LLC | 50 | $103 | 0.00% | 00.0% | Unchanged |
| FMR LLC | 37 | $76 | 0.00% | −113−75.3% | Reduced |
| JPMorgan Chase & Co | 34 | $70 | 0.00% | −19−35.8% | Reduced |
| Larson Financial Group LLC | 22 | $45 | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −82,152−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −27,624−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −25,299−100.0% | Sold out |
| Sassicaia Capital Advisers LLC | 0 | $0 | 0.00% | −15,000−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −593−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −99−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −83−100.0% | Sold out |